Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MIDODRINE HCL

8 Limited Use · 2 not a benefit

Apo-Midodrine · DIN 02278677 · 2.5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Midodrine · DIN 02278677 Manufacturer: Apotex Inc.; listing date 2006-08-24 Health Canada: Marketed since 2018-12-10 · brand APO-MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 2.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Midodrine: Formulary list price $0.1153/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1153 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76425 · Verify on the e-Formulary ↗ (DIN 02278677)

Source record
DIN 02278677: Apo-Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800041; group id 566; item number 1510; lccId 00079; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1153; ministry $0.1153 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02278677 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76425
Interchangeable products
Amatine · DIN 01934392 · not recorded Jamp Midodrine · DIN 02517701 · $0.1153 Mar-Midodrine · DIN 02473984 · $0.1153 Midodrine · DIN 02533200 · $0.1153
Shortage status: resolved shortage (ended 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02278677
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Midodrine · DIN 02517701 · 2.5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp Midodrine · DIN 02517701 Manufacturer: Jamp Pharma Corporation; listing date 2022-04-29 Health Canada: Marketed since 2022-02-21 · brand JAMP MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Midodrine: Formulary list price $0.1153/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1153 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100707 · Verify on the e-Formulary ↗ (DIN 02517701)

Source record
DIN 02517701: Jamp Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800041; group id 566; item number 1510; lccId 00079; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1153; ministry $0.1153 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517701 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100707
Interchangeable products
Amatine · DIN 01934392 · not recorded Apo-Midodrine · DIN 02278677 · $0.1153 Mar-Midodrine · DIN 02473984 · $0.1153 Midodrine · DIN 02533200 · $0.1153
Shortage status: resolved shortage (ended 2025-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517701
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Midodrine · DIN 02473984 · 2.5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Mar-Midodrine · DIN 02473984 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-08-03 · brand MAR-MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Midodrine: Formulary list price $0.1153/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1153 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96400 · Verify on the e-Formulary ↗ (DIN 02473984)

Source record
DIN 02473984: Mar-Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800041; group id 566; item number 1510; lccId 00079; manufacturer id MAR Source form: Tab; strength: 2.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1153; ministry $0.1153 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473984 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96400
Interchangeable products
Amatine · DIN 01934392 · not recorded Apo-Midodrine · DIN 02278677 · $0.1153 Jamp Midodrine · DIN 02517701 · $0.1153 Midodrine · DIN 02533200 · $0.1153
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473984
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Midodrine · DIN 02533200 · 2.5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Midodrine · DIN 02533200 Manufacturer: Sanis Health Inc.; listing date 2023-07-31 Health Canada: Marketed since 2023-05-31 · brand MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 2.5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Midodrine: Formulary list price $0.1153/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1153 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102221 · Verify on the e-Formulary ↗ (DIN 02533200)

Source record
DIN 02533200: Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800041; group id 566; item number 1510; lccId 00079; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1153; ministry $0.1153 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02533200 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102221
Interchangeable products
Amatine · DIN 01934392 · not recorded Apo-Midodrine · DIN 02278677 · $0.1153 Jamp Midodrine · DIN 02517701 · $0.1153 Mar-Midodrine · DIN 02473984 · $0.1153
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02533200
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Midodrine · DIN 02278685 · 5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Midodrine · DIN 02278685 Manufacturer: Apotex Inc.; listing date 2006-08-24 Health Canada: Marketed since 2018-12-10 · brand APO-MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Midodrine: Formulary list price $0.1921/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1921 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76426 · Verify on the e-Formulary ↗ (DIN 02278685)

Source record
DIN 02278685: Apo-Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800042; group id 566; item number 1511; lccId 00079; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1921; ministry $0.1921 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02278685 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76426
Interchangeable products
Amatine · DIN 01934406 · not recorded Jamp Midodrine · DIN 02517728 · $0.1921 Mar-Midodrine · DIN 02473992 · $0.1921 Midodrine · DIN 02533219 · $0.1921
Shortage status: resolved shortage (ended 2024-05-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02278685
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Midodrine · DIN 02517728 · 5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp Midodrine · DIN 02517728 Manufacturer: Jamp Pharma Corporation; listing date 2022-04-29 Health Canada: Marketed since 2025-08-07 · brand JAMP MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Midodrine: Formulary list price $0.1921/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1921 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100708 · Verify on the e-Formulary ↗ (DIN 02517728)

Source record
DIN 02517728: Jamp Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800042; group id 566; item number 1511; lccId 00079; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1921; ministry $0.1921 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517728 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100708
Interchangeable products
Amatine · DIN 01934406 · not recorded Apo-Midodrine · DIN 02278685 · $0.1921 Mar-Midodrine · DIN 02473992 · $0.1921 Midodrine · DIN 02533219 · $0.1921
Shortage status: resolved shortage (ended 2025-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517728
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Midodrine · DIN 02473992 · 5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Mar-Midodrine · DIN 02473992 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-08-03 · brand MAR-MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Midodrine: Formulary list price $0.1921/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1921 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96401 · Verify on the e-Formulary ↗ (DIN 02473992)

Source record
DIN 02473992: Mar-Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800042; group id 566; item number 1511; lccId 00079; manufacturer id MAR Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1921; ministry $0.1921 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473992 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96401
Interchangeable products
Amatine · DIN 01934406 · not recorded Apo-Midodrine · DIN 02278685 · $0.1921 Jamp Midodrine · DIN 02517728 · $0.1921 Midodrine · DIN 02533219 · $0.1921
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473992
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Midodrine · DIN 02533219 · 5mg · tablet

Limited Use — Reason for Use code 01 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 01 required
Write on scriptLU code 01 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Midodrine · DIN 02533219 Manufacturer: Sanis Health Inc.; listing date 2023-07-31 Health Canada: Marketed since 2023-05-31 · brand MIDODRINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Midodrine: Formulary list price $0.1921/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1921 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102222 · Verify on the e-Formulary ↗ (DIN 02533219)

Source record
DIN 02533219: Midodrine Raw flags: sec12=Y, sec3=Y Item: 402800042; group id 566; item number 1511; lccId 00079; manufacturer id SAI Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1921; ministry $0.1921 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02533219 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102222
Interchangeable products
Amatine · DIN 01934406 · not recorded Apo-Midodrine · DIN 02278685 · $0.1921 Jamp Midodrine · DIN 02517728 · $0.1921 Mar-Midodrine · DIN 02473992 · $0.1921
Shortage status: resolved shortage (ended 2025-03-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02533219
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Amatine · DIN 01934392 · 2.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-09-30 — choose a marketed DIN from the same-category list.Discontinued 2010-09-30 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-09-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-09-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Amatine · DIN 01934392 Manufacturer: Shire Pharma Canada ULC; listing date 1996-10-01 Health Canada: Cancelled post market since 2010-09-30 · brand AMATINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 2.5 MG · company Shire pharma canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Amatine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12428 · Verify on the e-Formulary ↗ (DIN 01934392)

Source record
DIN 01934392: Amatine Raw flags: notABenefit=Y, sec3=Y Item: 402800041; group id 566; item number 1510; lccId 00079; manufacturer id SHI Source form: Tab; strength: 2.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01934392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12428
Interchangeable products
Apo-Midodrine · DIN 02278677 · $0.1153 Jamp Midodrine · DIN 02517701 · $0.1153 Mar-Midodrine · DIN 02473984 · $0.1153 Midodrine · DIN 02533200 · $0.1153
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01934392
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-09-30 — choose a marketed DIN from the same-category list.

Amatine · DIN 01934406 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-10-04 — choose a marketed DIN from the same-category list.Discontinued 2010-10-04 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-10-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-10-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 01
Reason for Use code 01 For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Amatine · DIN 01934406 Manufacturer: Shire Pharma Canada ULC; listing date 1996-10-01 Health Canada: Cancelled post market since 2010-10-04 · brand AMATINE · ATC C01CA17 MIDODRINE · form Tablet · route Oral · ingredients MIDODRINE HYDROCHLORIDE 5 MG · company Shire pharma canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Amatine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12429 · Verify on the e-Formulary ↗ (DIN 01934406)

Source record
DIN 01934406: Amatine Raw flags: notABenefit=Y, sec3=Y Item: 402800042; group id 566; item number 1511; lccId 00079; manufacturer id SHI Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01934406 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12429
Interchangeable products
Apo-Midodrine · DIN 02278685 · $0.1921 Jamp Midodrine · DIN 02517728 · $0.1921 Mar-Midodrine · DIN 02473992 · $0.1921 Midodrine · DIN 02533219 · $0.1921
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01934406
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-10-04 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Because midodrine hydrochloride can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including non-pharmacologic treatment, plasma volume expansion and lifestyle alterations. The use of midodrine hydrochloride in the management of symptomatic orthostatic hypotension is based primarily on a change in a surrogate endpoint of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate endpoint considered likely to correspond to clinical benefits. At present, however, clinical benefits of midodrine hydrochloride, principally improved ability to carry out activities of daily life, have not been verified. APO-MIDODRINE (midodrine hydrochloride) may be used to attenuate symptoms of chronic orthostatic hypotension due to autonomic failure in patients with Bradbury-Eggleston syndrome, Shy-Drager syndrome, diabetes mellitus disease and Parkinson’s disease. The initiation and up-titration of midodrine therapy should be undertaken under close medical supervision in a controlled clinical setting (see DOSAGE AND ADMINIS… https://pdf.hres.ca/dpd_pm/00047855.PDF PM date: not printed or not captured Source product: APO-MIDODRINE; DIN 02278677; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Amatine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026